HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

被引：0
|
作者：
Hearn, Jason W. D.
AbuAli, Ghada
Magi-Galluzzi, Cristina
Reddy, Chandana A.
Chang, Kai-Hsiung
Klein, Eric A.
Sharifi, Nima
机构：
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[4] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[6] Cleveland Clin, Dept Canc Biol, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Cleveland Clin, Dept Urol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Response prediction with HSD3B1
    Thoma, Clemens
    NATURE REVIEWS UROLOGY, 2017, 14 (12) : 699 - 699
  • [42] HSD3B1 genotype and abiraterone (Abi) metabolites in patients (pts) with prostate cancer (PCa).
    Emamekhoo, Hamid
    Alyamani, Mohammad
    Park, Sunho
    Taylor, Jennifer
    Almassi, Nima
    Upadhyay, Sunil
    Tyler, Allison Janine
    Berk, Mike
    Hwang, Tae Hyun
    Grivas, Petros
    Rini, Brian I.
    Garcia, Jorge A.
    Auchus, Richard J.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [43] Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation
    Cui, Di
    Li, Jianneng
    Zhu, Ziqi
    Berk, Michael
    Hardaway, Aimalie
    McManus, Jeffrey
    Chung, Yoon-Mi
    Alyamani, Mohammad
    Valle, Shelley
    Tiwari, Ritika
    Han, Bangmin
    Goudarzi, Maryam
    Willard, Belinda
    Sharifi, Nima
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (07):
  • [44] A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer.
    Zhang, Jingsong
    Gallaher, Jill
    Wang, Liang
    Chatwal, Monica Sheila
    Kim, Youngchul
    Gatenby, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Response prediction with HSD3B1
    Clemens Thoma
    Nature Reviews Urology, 2017, 14 : 699 - 699
  • [46] Variant Allele of HSD3B1 Increases Progression to Castration-Resistant Prostate Cancer
    Wu, Gang
    Huang, Shengsong
    Nastiuk, Kent L.
    Li, Jinliang
    Gu, Jun
    Wu, Ming
    Zhang, Qimin
    Lin, Hanqing
    Wu, Denglong
    PROSTATE, 2015, 75 (07): : 777 - 782
  • [47] HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
    Hearn, Jason W. D.
    Sweeney, Christopher J.
    Almassi, Nima
    Reichard, Chad A.
    Reddy, Chandana A.
    Li, Hong
    Hobbs, Brian
    Jarrard, David F.
    Chen, Yu-Hui
    Dreicer, Robert
    Garcia, Jorge A.
    Carducci, Michael A.
    DiPaola, Robert S.
    Sharifi, Nima
    JAMA ONCOLOGY, 2020, 6 (04)
  • [48] Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?
    Thelen, P.
    Ringert, R. -H.
    Loertzer, H.
    Strauss, A.
    UROLOGE, 2012, 51 (09): : 1240 - 1245
  • [49] MicroRNA drivers of resistance to androgen deprivation therapy in prostate cancer
    Saunders, Philippa C.
    Fletcher, Claire
    CANCER RESEARCH, 2023, 83 (11)
  • [50] Risk of cognitive impairment associated with androgen deprivation therapy in prostate cancer.
    Verma, Shiv
    Shankar, Eswar
    Singh, Viabhav
    Gupta, Sanjay
    CANCER RESEARCH, 2022, 82 (12)
12345